WHAT IS CLAIMED IS:

1. A method of treating uterine serous papillary carcinoma in an individual in need of such treatment, comprising the step of administering to said individual a therapeutically effective dose of a HER-2/neu antibody.

2. The method of claim 1, wherein said antibody is a monoclonal antibody.

3. The method of claim 2, wherein said antibody is a humanized monoclonal antibody.

4. The method of claim 3, wherein said antibody is Herceptin®.

5. The method of claim 4, wherein said antibody is administered to said individual in a dose of from about 4 mg/kg to about 8 mg/kg.

6. The method of claim 1, further comprising the step of administering a therapeutically effective dose of interleukin-2 to said individual.

7. The method of claim 6, wherein said interleukin-2 is recombinant interleukin-2.

8. The method of claim 6, wherein said dose of interleukin-2 is non-toxic.

9. The method of claim 6, wherein said interleukin-2 is administered to said individual in a dose of from about 1×10^6 IU/M^2 to about 10×10^6 IU/M^2.

10. A method of differentiating primary uterine serous papillary carcinoma from serous papillary ovarian tumors in an individual, comprising the step of measuring the expression of HER-2/neu in said tissue, wherein the presence of an increased and constitutive expression pattern in said tissue indicates that said tumor is a uterine serous papillary carcinoma.

11. A method of treating uterine serous papillary carcinoma in an individual in need of such treatment, comprising the step of administering to said individual a therapeutically effective dose of a HER-2/neu antibody and a therapeutically effective dose of interleukin-2.

12. The method of claim 11, wherein said antibody is a monoclonal antibody.

13. The method of claim 12, wherein said antibody is a humanized monoclonal antibody.

14. The method of claim 13, wherein said antibody is Herceptin®.

15. The method of claim 14, wherein said antibody is administered to said individual in a dose of from about 4 mg/kg to about 8 mg/kg.

16. The method of claim 11, wherein said interleukin-2 is recombinant interleukin-2.

17. The method of claim 11, wherein said dose of interleukin-2 is non-toxic.

18. The method of claim 11, wherein said interleukin-2 is administered to said individual in a dose of from 1 x 10^6 IU/M^2 to about 10 x 10^6 IU/M^2g.